circulating tumor DNA
Foresight Diagnostics Launches Lymphoma Personalized Treatment Clinical Trial
The trial will study the use of Foresight's Clarity MRD assay in identifying early treatment responders for therapy de-escalation.
Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint
The guidance provides the agency's thoughts on the emerging use of ctDNA residual disease testing to select patients for treatment in trials of new adjuvant therapies.
OneCell Diagnostics Raises $16M in Series A Round
The precision oncology company plans to bring its OncoIndx Ikon liquid biopsy circulating tumor cell detection test to the US market.
A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
Pfizer's Ibrance Shows Benefit in Rare Appendix Cancer Study but Follow-on Research a Challenge
Premium
The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is a challenge for further investigations.
Jun 5, 2024